LOS ANGELES, Dec. 7, 2017 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
its presentation scheduled to be delivered at the LD Micro 10th
Annual Main Event Conference on Thursday,
December 7, 2017 has been canceled due to severe wildfires
in the Greater Los Angeles
area.
The 10th Annual LD Micro Main Event Conference, previously set
to be held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA, has been canceled by its
organizers as a safety precaution following road closures and
evacuation directives near the conference location. Consequently,
CytRx's presentation will not proceed as scheduled. The
conference organizers intend to reschedule for June 2018, and CytRx will provide updated
presentation details when they become available.
As previously announced, CytRx plans to present at the following
future investor conferences:
Biotech Showcase 2018
Tuesday, January 9, 2018 at
11:30 am PT
Hilton San Francisco Union Square,
San Francisco, CA
BIO CEO & Investor
Conference 2018
February 12-13, 2018 (exact date and
time TBD)
New York Marriott Marquis Hotel, New
York, NY
30th Annual ROTH Conference
March 11-13, 2018 (exact date and
time TBD)
The Ritz Carlton, Laguna Niguel,
CA
Presentation dates and times, along with any links to potential
webcasts, will be provided closer to the actual events.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical company specializing in
research and clinical development of novel anti-cancer drug
candidates that employ linker technologies to enhance the
accumulation and release of drug at the tumor. CytRx is also
rapidly expanding its pipeline of ultra-high potency oncology
candidates at its laboratory facilities in Freiburg, Germany,
through its LADR™ (Linker Activated Drug Release) technology
platform, a discovery engine designed to leverage CytRx's expertise
in albumin biology and linker technology for the development of a
new class of potential breakthrough anti-cancer therapies.
Aldoxorubicin, CytRx's most advanced drug conjugate, is an
improved version of the widely used anti-cancer drug doxorubicin
and has been out-licensed to NantCell, Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to plans for regaining compliance with the
Nasdaq rules and higher share price of our common stock; the
ability of NantCell, Inc., to obtain regulatory approval for its
products that use aldoxorubicin; the ability of NantCell, Inc., to
manufacture and commercialize products or therapies that use
aldoxorubicin; the amount, if any, of future milestone and royalty
payments that we may receive from NantCell, Inc.; our ability to
develop new ultra-high potency drug candidates based on our
LADRTM technology platform; and other risks and
uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and Exchange Commission
and current reports filed since the date of CytRx's most recent
annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-provides-update-on-presentations-at-upcoming-investor-conferences-300568276.html
SOURCE CytRx Corporation